Product Description: Afatinib is a kinase inhibitor indicated for the First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test & treatment of patients with metastatic, squamous NSCLC progressing after platinum-based chemotherapy. Afanix is available in tablet form for oral administration. The recommended dose of Afatinib is 40 mg orally, once daily until disease progression or no longer tolerated by the patient.
|Product Name||: Afanix|
|Generic Name||: Afatinib Dimaleate INN|
|Available Pack Size||: 30’s (3×10’s)|
|Available Strengths||: 40 mg|